Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

At Liraglutide Panel Review, A Call For CV Studies To Look Beyond MACE

Sep 22 2014

• By Sue Sutter

Related Content

Novo Nordisk’s Liraglutide Gets Panel Nod For Weight Management

Sep 15 2014

CV Risk Assessment For All Obesity Drugs Seems Inevitable Pre-Approval Requirement

Mar 30 2012

REMS Cannot Save Abbott's Obesity Drug Meridia In Face Of Cardiovascular Issues

Oct 08 2010

FDA Panel To Weigh Relevance Of Liraglutide’s Diabetes Experience In Obesity

Sep 09 2014

Will CV Verdicts For <em>Onglyza</em>, <em>Nesina</em> Cause FDA To Change Its Tune On Antidiabetic Safety?

Sep 09 2013

Related Companies

Novo Nordisk A/S

Abbott

Orexigen Therapeutics, Inc.

Takeda Pharmaceutical Co. Ltd.

Additional Topics

United States Advisory Committees BioPharmaceutical

More from United States

More from North America

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window